TrialsgrambetaRCTs are beautiful

SOLIDARITY

2021

WHO SOLIDARITY Trial

In 11,266 hospitalised COVID-19 patients across 405 hospitals, remdesivir, hydroxychloroquine, lopinavir or interferon did not reduce in-hospital mortality versus standard care.

Result

Primary endpoint: In-hospital mortality

No clear mortality benefit for any agent.

Original publication
Subtopic
Antivirals
Design
Adaptive open-label RCT, WHO
Enrolled
11,330 patients
Relevance
Important: one of several pillars.
Source
WHO Solidarity Trial Consortium. N Engl J Med. 2021;384(6):497-511.doi 10.1056/NEJMoa2023184

Discussion & critique

Pragmatic global RCT; tempered remdesivir enthusiasm and ended hydroxychloroquine.

Discussed in podcasts